LENZ Therapeutics Inc LENZ
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-06-25 |
| Shares Out. | 31,350,000 |
| Website | lenz-tx.com/ ↗ |
| Phone | 18589257000 |
| Employees | 152 |
| Revenue | $1.9M |
| Gross Profit | $825,000 |
| Net Income | -$41.5M |
| Free Cash Flow | -$87.4M |
| Total Assets | $272.5M |
| Total Liabilities | $26.0M |
| Equity | $246.5M |
About LENZ Therapeutics Inc
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
LENZ Therapeutics Inc is a publicly traded company under the ticker symbol LENZ on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)